← All organizations
Biocon Limited
For profitWebsite ↗
Also known as: Bicara Therapeutics | Biocon Biologics Inc. | BIOCON BIOLOGICS INC | Biocon Biologics UK Ltd | Biocon Biologics UK PLC | Biocon Limited | BIOCON LIMITED | BIOCON LTD | BIOCON PHARMA | BIOCON PHARMA LIMITED | BIOCON PHARMA LTD | Biocon Research Limited
Highest phase reached
Phase 3
Timeline
1970s
- Jun 1, 1978
Biocon Limited— Founded
2010s
- Dec 1, 2017
trastuzumab— NDA Secondary Org
- Apr 13, 2018
pravastatin— Marketing Organization
Drugs by trial phase (16 distinct, 23 trials)
Phase 3 (13 own, 0 via acquisition)
Phase 1 (3 own, 0 via acquisition)
Indications
Studied for
- Acute Lung Injury
- Asthma
- Carcinoma
- Carcinoma, Ovarian Epithelial
- Carcinoma, Squamous Cell
- Chordoma
- Coronavirus Infections
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Glioblastoma
- Graft vs Host Disease
- Lung Neoplasms
- Lupus Erythematosus, Systemic
- Lupus Nephritis
- Nephritis
- Pancreatic Neoplasms
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Squamous Cell Carcinoma of Head and Neck
- Syndrome
- Thyroid Carcinoma, Anaplastic
- Triple Negative Breast Neoplasms
Marketed drugs (34)
Recent trials (24)
- NCT07299955Lead sponsorPhase 1Jan 9, 2026
- NCT06788990Lead sponsorPhase 2/Phase 3Jan 28, 2025
- NCT06738277Lead sponsorPhase 1Jan 14, 2025
- NCT06038539Lead sponsorPhase 3Dec 15, 2023
- NCT05637515Lead sponsorPhase 3Nov 21, 2022
- NCT05335356Lead sponsorPhase 3Jun 28, 2022
- NCT05413863Lead sponsorPhase 1May 30, 2022
- NCT05345691Lead sponsorPhase 3May 24, 2022
- NCT05263999CollaboratorPhase 3Apr 29, 2022
- NCT05323708Lead sponsorPhase 1Mar 9, 2022
- NCT04605926CollaboratorPhase 3Nov 30, 2020
- NCT04429542Lead sponsorPhase 1Jun 1, 2020
- NCT04475588Lead sponsorPhase 2May 1, 2020
- NCT04141423Lead sponsorPhase 1Oct 28, 2019
- NCT04128579CollaboratorPhase 1Oct 1, 2019
Details
- Founded
- Bangalore, IN Jun 1, 1978
- Last known activity
- Mar 17, 2026